Adrian Florentin Suman

Dr. Adrian Florentin Suman

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Cells
Verified
Journal Article
Open access
PDF file
Melania GagginiMelania Gaggini
Melania Gaggini
Laura SabatinoLaura Sabatino
Laura Sabatino
ASAdrian Florentin Suman
Adrian Florentin Suman
KCKyriazoula Chatzianagnostou
Kyriazoula Chatzianagnostou
Cristina VassalleCristina Vassalle
Cristina Vassalle
In recent years, new drugs for the treatment of type 2 diabetes (T2D) have been proposed, including glucagon-like peptide 1 (GLP-1) agonists or sodium–glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. Over time, some of these agents (in particular, GLP-1 agonists and SGLT2 inhibitors), which were initially developed for their glucose-lowering actions, have demonstrated significant beneficial pleiotropic effects, thus expanding their potential therapeutic applications. This review aims to discuss the mechanisms, pleiotropic effects, and therapeutic potential of GLP-1, DPP-4, and SGLT2, with a particular focus on their cardiorenal benefits beyond glycemic control.

Verified
Journal Article
Open access
PDF file
KCKyriazoula Chatzianagnostou
Kyriazoula Chatzianagnostou
Melania GagginiMelania Gaggini
Melania Gaggini
ASAdrian Florentin Suman
Adrian Florentin Suman
LSLudovica Simonini
Ludovica Simonini
Cristina VassalleCristina Vassalle
Cristina Vassalle
Although good glycemic control in patients with type 2 diabetes (T2D) can prevent cardiovascular complications, many diabetic patients still have poor optimal control. A new class of antidiabetic drugs (e.g., glucagon-like peptide-1-GLP-1 receptor agonists, sodium-glucose co-transporters-SGLT2 inhibitors), in addition to the low hypoglycemic effect, exert multiple beneficial effects at a metabolic and cardiovascular level, through mechanisms other than antihyperglycemic agents. This review aims to discuss the effects of these new antidiabetic drugs, highlighting cardiovascular and metabolic benefits, through the description of their action mechanisms as well as available data by preclinical and clinical studies. Moreover, new innovative tools in the T2D field will be described which may help to advance towards a better targeted T2D personalized care in future.

1 March 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
Melania GagginiMelania Gaggini
Melania Gaggini
ASAdrian Florentin Suman
Adrian Florentin Suman
Cristina VassalleCristina Vassalle
Cristina Vassalle
Lipids are a complex entity of different molecules, among which ceramides (Cers), ubiquitous sphingolipids with remarkable biological activity, can represent a potential additive biomarker that can be used to better understand the underlying mechanisms which drive the onset and development of atherosclerotic damage and plaque vulnerability and facilitate coronary disease management, as possible risk/prognostic biomarkers and targets for therapeutic intervention. Accordingly, this review aims to discuss the available results on the role Cersplay in contributing to atherosclerosis development and acute coronary event precipitation, their impact on complications and adverse prognosis, as well as the impact of treatment options in modulating Cerlevels.

20 September 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ASAdrian Florentin Suman
Adrian Florentin Suman
DLDavide De Luca
Davide De Luca
Melania GagginiMelania Gaggini
Melania Gaggini
FCFrancesco Cucco
Francesco Cucco
Diffuse large B-cell lymphoma (DLBCL) is a molecular and clinical heterogenous entity, and, over the past 30 years, many efforts have been made in trying to dissect this diverseness and identify biomarkers capable of efficiently stratifying DLBCL patients and spotting the ones showing a worse clinical outcome. Despite the achievement in this research field, only a few biomarkers have been validated and introduced in a clinical setting. Among those, approximately 5–15% of DLBCL cases harbor MYC gene translocations, often involving immunoglobulin genes as a translocation partner, and concomitant point mutations, correlating with a poor response to standard therapies. However, given the difficulty in detecting these abnormalities requiring specialized techniques and high-quality specimens, the use of metabolomics (i.e., the study of small metabolites in body fluids and tissues) can offer a useful alternative for the identification of high-risk DLBCL patients. Amino acids (AAs) are metabolites essential in the process of tumorigenesis and can increase immune escape and drug resistance. Therefore, we review the use of metabolomics to improve the diagnosis and prognosis in DLBCL patients in relation to the MYC role in the regulation of amino acid metabolism, as these metabolites may be used as potential biomarkers in a clinical environment.

14 April 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
Melania GagginiMelania Gaggini
Melania Gaggini
ASAdrian Florentin Suman
Adrian Florentin Suman
Cristina VassalleCristina Vassalle
Cristina Vassalle
Ceramides, sphingolipids produced from fatty acids linked to sphingosine and an amide, are structural elements of cellular membranes and lipoproteins. These molecules also retain biological effects in key cellular pathways such as oxidative stress and inflammation, apoptosis, and fibrosis, with a role in the onset and development of many pathophysiological conditions, including obesity, diabetes, and insulin resistance. Increasing evidence suggests that different nutrients and dietary patterns may affect ceramide levels, both negatively (e.g., fructose and the Western diet), whereas others improve the ceramide profile (e.g., ω-3 PUFAs, resveratrol, vitamin D, and the Mediterranean and the Nordic diets). Thus, ceramide nutritional modulation could represent a simple, additive, and reliable tool to improve metabolic health. This review focused on the role of ceramides in the pathophysiology of diabetes and obesity, as well as their pathogenetic mechanisms of action. Ceramides are increasingly recognized as “dynamic metabolic interfaces” linking nutrition and disease. This review aims to address a critical gap by synthesizing recent evidence on how dietary interventions, in addition to pharmacological approaches, can specifically target the enzymatic pathways involved in ceramide synthesis to enhance metabolic health. Thus, this review offers a concentrated analysis of the response of specific ceramide species, such as Cer16:0 and Cer18:0, to distinct dietary factors. Additionally, it incorporates emerging evidence on the role of gut microbiota in the biotransformation of sphingolipids, thereby adding a contemporary dimension to the established nutritional perspective.

16 September 2024 in Hearts
Verified
Journal Article
Open access
PDF file
SSSilverio Sbrana
Silverio Sbrana
SSStefano Salvadori
Stefano Salvadori
RRRosetta Ragusa
Rosetta Ragusa
ECElisa Ceccherini
Elisa Ceccherini
ASAdrian Florentin Suman
Adrian Florentin Suman
SRSilvia Rocchiccioli
Silvia Rocchiccioli
Atherosclerosis is an inflammatory disease wherein neutrophils play a key role in plaque evolution. We observed that neutrophil CD11b was associated with a higher necrotic core volume in coronary plaques. Since platelets modulate neutrophil function, we explored the influence of neutrophil–platelet conjugates on the cytokine-modulated neutrophil complex CD11b/CD18 and CCR5 receptor expression. In 55 patients [68.53 ± 7.95 years old (mean ± SD); 71% male], neutrophil positivity for CD11b, CD18 and CCR5 was expressed as Relative Fluorescence Intensity (RFI) and taken as a dependent variable. Cytokines and chemokines were assessed by ELISA. Following log-10-based logarithmic transformation, they were used as independent variables in Model 1 of multiple regression together with Body Mass Index and albumin. Model 1 was expanded with the RFI of neutrophil CD41a+ (model 2). The RFI of neutrophil CD41a+ correlated positively and significantly with CD11b, CD18, and CCR5. In Model 2, CCR5 correlated positively only with the RFI of neutrophil CD41a+. Albumin maintained its positive effect on CD11b in both models. These observations indicate the complexity of neutrophil phenotypic modulation in stable CAD. Despite limitations, these findings suggest there is a role played by neutrophil–platelet interaction on the neutrophil cytokine-modulated expression of adhesive and chemotactic receptors.